Allurion Technologies is a technology company.
Allurion Technologies has raised $67.0M across 3 funding rounds.
Allurion Technologies has raised $67.0M in total across 3 funding rounds.
Allurion Technologies has raised $67.0M in total across 3 funding rounds.
Allurion Technologies's investors include 3one4 Capital, DFJ, REMUS Capital.
Allurion Technologies is a biotechnology company developing the world's first full-stack, non-surgical weight-loss platform to end obesity globally.[1][2][3] Its core product, the Allurion Balloon, is a gastric balloon placed and removed without routine surgery, endoscopy, or anesthesia, paired with the Allurion Virtual Care Suite—including a mobile app, clinician insights platform, connected scale, and health tracker—for comprehensive patient and provider support.[2][3] The program targets adults struggling with obesity, solving the problems of invasive surgeries, high costs, hunger from diets, and lack of sustained habits by enabling 10-15% total body weight loss in 4 months (16 weeks) through medical, digital, and nutritional guidance.[2][3][4] With over 100,000 balloons distributed worldwide and strong clinical evidence, Allurion shows robust growth momentum outside the U.S., where the balloon awaits approval.[2][4]
Allurion Technologies was founded in 2009 by Shantanu Gaur and Samuel Levy, medical students at Harvard Medical School who challenged conventional weight-loss approaches by directly engaging patients.[3][4] Observing frustrations with yo-yo dieting, hunger, expensive invasive surgeries, and lack of lifelong empowerment, they envisioned a simple, accessible program combining innovative medical tech with behavioral support.[4] This led to the Allurion Balloon and Program, which gained early traction through patient-centered design; today, it has reached over 100,000 users globally, fulfilling their mission to catalyze permanent weight loss.[2][4]
Allurion rides the global obesity epidemic trend, where healthcare systems struggle with rising prevalence, demanding scalable, consumer-empowered solutions beyond diets or surgery.[3][4] Its timing aligns with advances in procedural tech and digital health, enabling non-invasive interventions amid demands for accessible care without medical complexities.[2][3] Favorable market forces include growing acceptance of swallowable devices, telemedicine integration, and evidence-based weight management, positioning Allurion to disrupt a multi-billion-dollar industry strained by surgical limitations.[2][4] By prioritizing patient stories and data, it influences the ecosystem toward holistic, tech-enabled obesity solutions, potentially accelerating adoption in underserved regions.[3][4]
Allurion is poised for expansion with U.S. approval, scaling its balloon program and Virtual Care Suite to capture mainstream markets amid surging obesity interventions.[2] Trends like AI-driven personalization in health apps and wearable integration will enhance its data-centric model, while global partnerships could boost distribution beyond 100,000 units.[2][3][4] Its influence may evolve from niche disruptor to obesity standard-setter, empowering fuller lives—if it navigates regulatory hurdles and sustains clinical momentum—ultimately realizing the founders' vision of ending obesity through audacious, patient-first innovation.[3][4]
Allurion Technologies has raised $67.0M across 3 funding rounds. Most recently, it raised $34.0M Venture Round in January 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2020 | $34.0M Venture Round | 3one4 Capital, DFJ, REMUS Capital | |
| Jul 1, 2017 | $27.0M Series C | 3one4 Capital, DFJ, REMUS Capital | |
| May 1, 2016 | $6.0M Venture Round | 3one4 Capital, DFJ, REMUS Capital |